Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Inhibikase Therapeutics (IKT)

Annual Return

Over the past 3 years, IKT has had an average annual return of -6.59%, underperforming the benchmark SPY, which returned +19.62% annual.

Over the past 5 years, IKT has had an average annual return of -31.62%, underperforming the benchmark SPY, which returned +12.73% annual.

Since Dec 23, 2020, IKT has had an average annual return of -44.49%, underperforming the benchmark SPY, which returned +15.12% annual.

2026202520242023202220212020
+8.70%-36.93%+155.61%-57.62%-65.99%-78.69%-30.30%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026-26.67%+36.36%-17.97%+12.37%-7.23%+15.93%+9.65%+8.70%
2025-30.16%+1.31%-4.65%+2.98%-11.05%-2.96%-18.90%+13.91%-9.90%-9.52%+3.64%+34.77%-36.93%
2024+137.38%-28.35%-0%-32.14%+25.51%-34.19%+16.18%-0.42%-7.20%+94.52%+15.49%+11.18%+155.61%
2023+41.19%+4.63%-10.99%-15.06%+23.23%-12.52%-30.26%-20.28%-30.77%-36.32%+6.04%+35.44%-57.62%
2022-4.78%-24.26%+39.59%-27.02%-15.22%-18.92%+14.40%+12.94%-5.16%-15.13%-21.67%-17.35%-65.99%
2021-3.49%+0.61%-10.30%-12.98%+2.29%-47.67%-18.92%+4.40%-19.84%+4.74%+0.50%-26.49%-78.69%
2020-30.30%-30.30%

Drawdown analysis of Inhibikase Therapeutics (IKT)

The maximum drawdown for the IKT was -98.64%, occurring on Oct 9, 2023. This drawdown has not yet recovered.

The current IKT drawdown is -96.25%.

Since Dec 23, 2020 IKT has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 1 time
  • 20% or more: 1 time
  • 10% or more: 1 time
DepthStartTo BottomBottomTo RecoverEndTotal
-98.64%Dec 23, 2020701Oct 9, 2023OngoingOngoingOngoing